[go: up one dir, main page]

PE20011305A1 - Agentes diazabiciclicos activos en el snc - Google Patents

Agentes diazabiciclicos activos en el snc

Info

Publication number
PE20011305A1
PE20011305A1 PE2001000385A PE2001000385A PE20011305A1 PE 20011305 A1 PE20011305 A1 PE 20011305A1 PE 2001000385 A PE2001000385 A PE 2001000385A PE 2001000385 A PE2001000385 A PE 2001000385A PE 20011305 A1 PE20011305 A1 PE 20011305A1
Authority
PE
Peru
Prior art keywords
alkyl
link
pyridinyl
cis
diazabicyclic
Prior art date
Application number
PE2001000385A
Other languages
English (en)
Inventor
Richard B Toupence
Anwer Basha
William H Bunnelle
Jerome F Daanen
Karin R Tietje
Jennifer Mary Pace
Michael R Schrimpf
Kevin B Sippy
Jianguo Ji
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20011305A1 publication Critical patent/PE20011305A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A AGENTES DIAZABICICLICOS DE FORMULA I DONDE A ES UN ENLACE, CH2, (CH2)2, (CH2)3; B ES CH2, (CH2)2; SI A ES (CH2)3, B ES CH2; Y ES ENLACE, CH2, (CH2)2; Z ES ENLACE, CH2, (CH2)2, SI Y ES (CH2)2; Z ES ENLACE SI Z ES (CH2)2 Y ES ENLACE; R1 ES UN GRUPO a, b, c; R3 ES H, ALQUILO, HALOGENO; R4 ES H, ALCOXILO, ALQUILO, ENTRE OTROS; R5 ES H, ALQUENILO, ALCOXILO, ENTRE OTROS; R6, R7 R8 SON H, ALQUILO; R9 ES H, ALCOXICARBONILO, ALQUILO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (CIS)-6-(3-PIRIDINIL)-3,6-DIAZABICICLO[3.2.0]HEPTANO, (CIS)-8-(3-PIRIDINIL)-3,8-DIAZABICICLO[4.2.0]OCTANO, (CIS)-1-(6-CLORO-3-PIRIDINIL)OCTAHIDROPIRROLO[3,4-b]PIRROL. EL COMPUESTO I O EN COMBINACION CON ANTIINFLAMATORIO NO ESTEROIDEO, OPIOIDE, ANTIDEPRESIVO TRICICLICO, ANTICONVULSIVANTE PUEDE SER UTIL PARA CONTROLAR LA LIBERACION DE UN NEUROTRASMISOR COMO ALZHEIMER, MAL DE PARKINSON, TRASTORNO DE HIPERACTIVIDAD CON DEFICIT DE ATENCION, DEPRESION, SINDROME DE ABANDONO DE NICOTINA, SINDROME DE TOURETTE, ESQUIZOFRENIA
PE2001000385A 2000-04-27 2001-04-27 Agentes diazabiciclicos activos en el snc PE20011305A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents

Publications (1)

Publication Number Publication Date
PE20011305A1 true PE20011305A1 (es) 2001-12-31

Family

ID=27072208

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000385A PE20011305A1 (es) 2000-04-27 2001-04-27 Agentes diazabiciclicos activos en el snc

Country Status (22)

Country Link
EP (3) EP2298775A1 (es)
JP (2) JP4981232B2 (es)
KR (4) KR100961406B1 (es)
CN (3) CN102863441A (es)
AR (1) AR030421A1 (es)
AU (2) AU2001266559C1 (es)
BG (2) BG66151B1 (es)
BR (1) BR0107246A (es)
CA (2) CA2683045A1 (es)
CZ (4) CZ302795B6 (es)
HK (1) HK1054375A1 (es)
HU (1) HUP0300602A3 (es)
IL (3) IL152231A0 (es)
MX (1) MXPA02010594A (es)
MY (3) MY137020A (es)
NO (1) NO324250B1 (es)
NZ (1) NZ521734A (es)
PE (1) PE20011305A1 (es)
PL (2) PL398491A1 (es)
SK (2) SK287658B6 (es)
TW (4) TWI311137B (es)
WO (1) WO2001081347A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380031T1 (de) 1999-12-10 2007-12-15 Pfizer Prod Inc Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
PL377791A1 (pl) * 2002-11-21 2006-02-20 Pfizer Products Inc. Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
CA2565211A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
ES2391472T3 (es) * 2005-12-20 2012-11-27 Astrazeneca Ab Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US8163916B2 (en) 2007-03-23 2012-04-24 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
WO2009036132A1 (en) 2007-09-11 2009-03-19 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
PA8802501A1 (es) 2007-10-31 2009-06-23 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
EP2231672B1 (en) * 2007-11-21 2014-12-17 AbbVie Inc. BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2009071690A2 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707669C (en) 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
ES2380398T3 (es) 2007-12-18 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados 5-aminociclilmetil-oxazolidin-2-ona
BRPI0911336A2 (pt) 2008-04-11 2021-06-29 Janssen Pharmaceutica N.V. tiazolopiridin-2-iloxifenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
EP2411012A4 (en) * 2009-03-24 2012-08-22 Msd Kk NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION
NZ596137A (en) 2009-05-14 2013-08-30 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
RS54945B1 (sr) 2009-10-23 2016-11-30 Janssen Pharmaceutica Nv Disupstituisani oktahidropirolo[3,4-c]piroli kao oreksin receptor modulatori
US9062044B2 (en) * 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
KR20170090422A (ko) 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물
DK3426251T3 (da) 2016-03-10 2022-06-20 Janssen Pharmaceutica Nv Fremgangsmåder til behandling af depression under anvendelse af orexin-2-receptorantagonister
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
CN109843872B (zh) * 2017-09-20 2022-08-30 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CR20210240A (es) 2018-11-14 2021-06-08 Janssen Pharmaceutica Nv Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina
EP3978497A4 (en) * 2019-05-30 2022-07-13 Shanghai Institute of Materia Medica, Chinese Academy of Sciences FUSED CYCLIC COMPOUND, METHOD FOR PREPARING IT AND ITS USE
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393424T3 (da) 1989-04-17 1996-02-05 Bayer Ag Fremgangsmåde til fremstilling af 2,7-diazabicyclo(3.3.0)octaner
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
CA2112165C (en) 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JP4176147B2 (ja) * 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
AU736798B2 (en) * 1997-05-30 2001-08-02 Neurosearch A/S 9-Azabicyclo(3.3.1)non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ACh receptors
ATE267199T1 (de) * 1997-05-30 2004-06-15 Neurosearch As 8-azabicyclo(3,2,1)oct-2-en- und octanderivate als liganden der nicotinergen ach rezeptoren
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
PT1027336E (pt) * 1997-10-27 2005-01-31 Neurosearch As Heteroarildiazacicloalcanos como ligandos colinergicos de receptores nocotinicos de acetilcolina
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DK1068208T3 (da) * 1998-04-02 2003-09-01 Targacept Inc Azatricyclo[3.3.1.1]dekanderivater og farmaceutiske sammensætninger, der indeholder dem
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1359152B1 (en) * 1999-01-29 2008-05-07 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
EP1177196B1 (en) * 1999-05-04 2004-03-10 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
CZ20014127A3 (cs) * 1999-05-21 2002-06-12 Abbott Laboratories Heterocyklické substituované aminoazacykly uľitečné jako prostředky ovlivňující centrální nervový systém
CA2389553C (en) * 1999-12-14 2010-06-22 Neurosearch A/S Heteroaryl-diazabicycloalkanes

Also Published As

Publication number Publication date
CA2407094A1 (en) 2001-11-01
WO2001081347A3 (en) 2002-01-31
BG107303A (bg) 2003-07-31
NO20025107D0 (no) 2002-10-24
KR20090013833A (ko) 2009-02-05
SK287658B6 (sk) 2011-05-06
IL177316A0 (en) 2006-12-10
CZ302795B6 (cs) 2011-11-16
CZ302072B6 (cs) 2010-09-29
IL152231A0 (en) 2003-05-29
KR20020093955A (ko) 2002-12-16
CA2683045A1 (en) 2001-11-01
JP2012041349A (ja) 2012-03-01
PL358340A1 (en) 2004-08-09
NO324250B1 (no) 2007-09-17
TW200617013A (en) 2006-06-01
KR100947188B1 (ko) 2010-03-12
TWI311137B (en) 2009-06-21
EP2298775A1 (en) 2011-03-23
MY145722A (en) 2012-03-30
KR100961406B1 (ko) 2010-06-09
HUP0300602A3 (en) 2005-12-28
TW200909432A (en) 2009-03-01
CN1440410A (zh) 2003-09-03
TWI357903B (en) 2012-02-11
BG110620A (bg) 2010-07-30
MY168244A (en) 2018-10-15
AU6655901A (en) 2001-11-07
AU2001266559C1 (en) 2005-11-17
BG66151B1 (bg) 2011-08-31
CZ302038B6 (cs) 2010-09-15
JP2003531210A (ja) 2003-10-21
NZ521734A (en) 2004-10-29
CN100430398C (zh) 2008-11-05
KR20090121385A (ko) 2009-11-25
CZ20023765A3 (cs) 2003-02-12
HK1054375A1 (zh) 2003-11-28
BR0107246A (pt) 2002-10-01
CN102863441A (zh) 2013-01-09
MY137020A (en) 2008-12-31
KR100947187B1 (ko) 2010-03-12
CZ301324B6 (cs) 2010-01-13
AR030421A1 (es) 2003-08-20
AU2001266559B2 (en) 2005-03-03
EP2295437A1 (en) 2011-03-16
IL203035A (en) 2010-12-30
KR100899950B1 (ko) 2009-05-28
MXPA02010594A (es) 2003-05-14
JP4981232B2 (ja) 2012-07-18
TW201141871A (en) 2011-12-01
WO2001081347A2 (en) 2001-11-01
KR20090071654A (ko) 2009-07-01
EP1284976A2 (en) 2003-02-26
CN101935322A (zh) 2011-01-05
TWI323733B (en) 2010-04-21
PL398491A1 (pl) 2012-06-04
NO20025107L (no) 2002-12-19
SK16812002A3 (sk) 2003-04-01
CA2407094C (en) 2009-11-17
IL177316A (en) 2010-06-30
SK287273B6 (sk) 2010-05-07
HUP0300602A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
PE20011305A1 (es) Agentes diazabiciclicos activos en el snc
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20030415A1 (es) Derivados policiclicos de guanina como inhibidores de fosfodiesterasa v
PE20090279A1 (es) Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
DE60042762D1 (de) Zwischenprodukte für die Herstellung von Harnstoffderivaten mit Muskarinrezeptor-antagonistischer Aktivität
PE20030292A1 (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20010681A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
BR0115400A (pt) Compostos de piperazinilpirazina atuando como agonistas ou antagonistas do receptor 5ht-2 de serotonina
EA199900502A1 (ru) 8-азабицикло[3.2.1]октан-, 8-азабицикло[3.2.1]окт-6-ен-, 9-азабицикло[3.3.1]нонан-, 9-аза-3-оксабицикло[3.3.1]нонан- и 9-аза-3-тиабицикло[3.3.1]нонанпроизводные, их получение и их применение в качестве инсектицидов
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
DE602004016516D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
PE20030129A1 (es) Imidazotriazinas
ES2174836T3 (es) Heterrociclos nitrogenados triciclicos condesados como antagonistas de receptor de la sustancia p.
PE20020514A1 (es) Aminas heterociclicas y fenilazacicloalcanos sustituidos para el tratamiento del sindrome de piernas inquietas
PE20060010A1 (es) 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C
PE20010736A1 (es) PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed